523 related articles for article (PubMed ID: 27807830)
1. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
2. Proteasome-associated deubiquitinases and cancer.
Mofers A; Pellegrini P; Linder S; D'Arcy P
Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.
Park J; Cho J; Song EJ
Arch Pharm Res; 2020 Nov; 43(11):1144-1161. PubMed ID: 33165832
[TBL] [Abstract][Full Text] [Related]
4. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
5. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
6. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
7. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitination: Friend and foe in cancer.
Mansour MA
Int J Biochem Cell Biol; 2018 Aug; 101():80-93. PubMed ID: 29864543
[TBL] [Abstract][Full Text] [Related]
9. The significance of ubiquitin proteasome pathway in cancer development.
Yerlikaya A; Yöntem M
Recent Pat Anticancer Drug Discov; 2013 Sep; 8(3):298-309. PubMed ID: 23061719
[TBL] [Abstract][Full Text] [Related]
10. N-Terminal-Dependent Protein Degradation and Targeting Cancer Cells.
Eldeeb MA
Anticancer Agents Med Chem; 2021; 21(2):231-236. PubMed ID: 32814541
[TBL] [Abstract][Full Text] [Related]
11. GSK-3β signaling determines autophagy activation in the breast tumor cell line MCF7 and inclusion formation in the non-tumor cell line MCF10A in response to proteasome inhibition.
Gavilán E; Sánchez-Aguayo I; Daza P; Ruano D
Cell Death Dis; 2013 Apr; 4(4):e572. PubMed ID: 23559006
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells.
Li X; Zhu F; Jiang J; Sun C; Zhong Q; Shen M; Wang X; Tian R; Shi C; Xu M; Peng F; Guo X; Hu J; Ye D; Wang M; Qin R
Autophagy; 2016 Sep; 12(9):1521-37. PubMed ID: 27308733
[TBL] [Abstract][Full Text] [Related]
13. Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Watanabe M; Funakoshi T; Unuma K; Aki T; Uemura K
Toxicology; 2014 Aug; 322():43-50. PubMed ID: 24801902
[TBL] [Abstract][Full Text] [Related]
14. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
15. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
16. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
Driscoll JJ; Brailey M
Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on the development of first-in-class protein degraders.
Rambacher KM; Calabrese MF; Yamaguchi M
Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
[TBL] [Abstract][Full Text] [Related]
18. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
19. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
20. Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
Lub S; Maes K; Menu E; De Bruyne E; Vanderkerken K; Van Valckenborgh E
Oncotarget; 2016 Feb; 7(6):6521-37. PubMed ID: 26695547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
